These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17180691)

  • 41. Standardisation of a coproantigen reduction test (CRT) protocol for the diagnosis of resistance to triclabendazole in Fasciola hepatica.
    Flanagan AM; Edgar HW; Forster F; Gordon A; Hanna RE; McCoy M; Brennan GP; Fairweather I
    Vet Parasitol; 2011 Feb; 176(1):34-42. PubMed ID: 21093156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative efficacy of clorsulon and albendazole against Fasciola hepatica in cattle.
    Kilgore RL; Williams ML; Benz GW; Gross SJ
    Am J Vet Res; 1985 Jul; 46(7):1553-5. PubMed ID: 4026039
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current Threat of Triclabendazole Resistance in Fasciola hepatica.
    Kelley JM; Elliott TP; Beddoe T; Anderson G; Skuce P; Spithill TW
    Trends Parasitol; 2016 Jun; 32(6):458-469. PubMed ID: 27049013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High prevalence of fasciolosis and evaluation of drug efficacy against Fasciola hepatica in dairy cattle in the Maffra and Bairnsdale districts of Gippsland, Victoria, Australia.
    Elliott TP; Kelley JM; Rawlin G; Spithill TW
    Vet Parasitol; 2015 Apr; 209(1-2):117-24. PubMed ID: 25771931
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immature Fasciola gigantica: Time-dependent ultrastructural changes following in vivo treatment with triclabendazole.
    P A AS; S M A A
    Acta Trop; 2019 Aug; 196():15-21. PubMed ID: 31028722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A scanning electron microscope study on the route of entry of clorsulon into the liver fluke, Fasciola hepatica.
    Meaney M; Haughey S; Brennan GP; Fairweather I
    Parasitol Res; 2005 Jan; 95(2):117-28. PubMed ID: 15592937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence for high genetic diversity of NAD1 and COX1 mitochondrial haplotypes among triclabendazole resistant and susceptible populations and field isolates of Fasciola hepatica (liver fluke) in Australia.
    Elliott T; Muller A; Brockwell Y; Murphy N; Grillo V; Toet HM; Anderson G; Sangster N; Spithill TW
    Vet Parasitol; 2014 Feb; 200(1-2):90-6. PubMed ID: 24360656
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Understanding triclabendazole resistance.
    Brennan GP; Fairweather I; Trudgett A; Hoey E; McCoy ; McConville M; Meaney M; Robinson M; McFerran N; Ryan L; Lanusse C; Mottier L; Alvarez L; Solana H; Virkel G; Brophy PM
    Exp Mol Pathol; 2007 Apr; 82(2):104-9. PubMed ID: 17398281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ultrastructural changes to the tegumental system and gastrodermal cells of adult Fasciola hepatica following treatment in vivo with a commercial preparation of myrrh (Mirazid).
    Abdelaal MMO; Brennan GP; Abdel-Aziz A; Fairweather I
    J Helminthol; 2017 Nov; 91(6):672-685. PubMed ID: 27762182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disruption of egg production by triclabendazole-resistant Fasciola hepatica following treatment with a commercial preparation of myrrh (Mirazid).
    Abdelaal MMO; Brennan GP; Hanna REB; Abdel-Aziz A; Fairweather I
    Acta Parasitol; 2017 Jun; 62(2):336-347. PubMed ID: 28426420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immature triclabendazole-resistant Fasciola hepatica: tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.
    McConville M; Brennan GP; McCoy M; Castillo R; Hernandez-Campos A; Ibarra F; Fairweather I
    Parasitol Res; 2007 Jan; 100(2):365-77. PubMed ID: 17016729
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative proteomic analysis of triclabendazole response in the liver fluke Fasciola hepatica.
    Chemale G; Perally S; LaCourse EJ; Prescott MC; Jones LM; Ward D; Meaney M; Hoey E; Brennan GP; Fairweather I; Trudgett A; Brophy PM
    J Proteome Res; 2010 Oct; 9(10):4940-51. PubMed ID: 20726552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The T687G SNP in a P-glycoprotein gene of Fasciola hepatica is not associated with resistance to triclabendazole in two resistant Australian populations.
    Elliott TP; Spithill TW
    Mol Biochem Parasitol; 2014 Nov; 198(1):45-7. PubMed ID: 25481750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative assessment of the access of albendazole, fenbendazole and triclabendazole to Fasciola hepatica: effect of bile in the incubation medium.
    Alvarez LI; Mottier ML; Lanusse CE
    Parasitology; 2004 Jan; 128(Pt 1):73-81. PubMed ID: 15002906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fasciola hepatica: time-dependent disruption of spermatogenesis following in vivo treatment with triclabendazole.
    Toner E; Brennan GP; Hanna RE; Edgar HW; Fairweather I
    Parasitol Res; 2011 Oct; 109(4):1035-43. PubMed ID: 21541756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fasciola hepatica: influence of gender and liver biotransformations on flukicide treatment efficacy of rats infested and cured with either clorsulon/ivermectin or triclabendazole.
    Sibille P; Calléja C; Carreras F; Bigot K; Galtier P; Boulard C
    Exp Parasitol; 2000 Apr; 94(4):227-37. PubMed ID: 10831390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance of Fasciola hepatica against Triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep.
    Ortiz P; Scarcella S; Cerna C; Rosales C; Cabrera M; Guzmán M; Lamenza P; Solana H
    Vet Parasitol; 2013 Jul; 195(1-2):118-21. PubMed ID: 23352107
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of compound alpha treatment in vivo on egg production by the liver fluke, Fasciola hepatica.
    McConville M; Hanna RE; Brennan GP; Edgar HW; McConnell S; McCoy M; Castillo R; Hernández-Campos A; Fairweather I
    Vet Parasitol; 2012 Jun; 187(1-2):183-95. PubMed ID: 22285009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surface and internal tegumental changes in juvenile Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha.
    McConville M; Brennan GP; Flanagan A; Edgar HW; McCoy M; Castillo R; Hernández-Campos A; Fairweather I
    Vet Parasitol; 2008 May; 153(1-2):52-64. PubMed ID: 18359570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole.
    Sanabria R; Ceballos L; Moreno L; Romero J; Lanusse C; Alvarez L
    Vet Parasitol; 2013 Mar; 193(1-3):105-10. PubMed ID: 23273779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.